NEXTO NEXTO
Zoekresultaten
Alle resultaten weergeven
  • Registreer
    Log in
    Creëer je account
    Zoeken
    Night Mode

Zoeken

Ontdek nieuwe mensen, nieuwe verbindingen te maken en nieuwe vrienden maken

  • Nieuws Feed
  • ECOSYSTEM
  • EXPLORE
  • Pagina
  • Groepen
  • Events
  • Blogs
  • Berichten
  • Blogs
  • Gebruikers
  • Pagina
  • Groepen
  • Events
  • Shreya Patil toegevoegd een audio Other
    2025-12-15 07:41:57 -
    Breast Cancer Diagnostics Market Size, Share, Demand, Rising Trends, Growth and Competitors Analysis
    Breast Cancer Diagnostics Market By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centers, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others)...
    0 Reacties 0 aandelen 288 Views 0 voorbeeld
    Please log in to like, share and comment!
  • Shreya Patil toegevoegd een audio Other
    2025-12-22 07:14:16 -
    Breast Cancer Diagnostics Market Size, Share, Trends, Key Drivers, Growth Opportunities and Competitive Outlook
    Breast Cancer Diagnostics Market By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centers, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others) Industry...
    0 Reacties 0 aandelen 242 Views 0 voorbeeld
    Please log in to like, share and comment!
  • Sai Datam toegevoegd een audio Health
    2025-09-18 06:54:42 -
    ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Emerging Opportunities
    ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size The ESR1 Mutated Metastatic Breast Cancer Diagnostics Market is an emerging, clinically important segment of oncology diagnostics driven by the need to detect acquired resistance to endocrine therapy in hormone-receptor (HR+) metastatic breast cancer. Market estimates place the diagnostics segment at roughly US$ 60–65 million...
    0 Reacties 0 aandelen 790 Views 0 voorbeeld
    Please log in to like, share and comment!
© 2026 NEXTO Dutch
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek
About Voorwaarden Privacy Community Guidelines Tokenomics Roadmap & Updates Security & Safety Tips FAQ Cookie Policy Contact Us Bedrijvengids